CA2979676A1 - Methodes de suivi de la reponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire - Google Patents

Methodes de suivi de la reponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire

Info

Publication number
CA2979676A1
CA2979676A1 CA2979676A CA2979676A CA2979676A1 CA 2979676 A1 CA2979676 A1 CA 2979676A1 CA 2979676 A CA2979676 A CA 2979676A CA 2979676 A CA2979676 A CA 2979676A CA 2979676 A1 CA2979676 A1 CA 2979676A1
Authority
CA
Canada
Prior art keywords
her2
response
cancer
cells
thl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2979676A
Other languages
English (en)
Inventor
Brian J. Czerniecki
Gary K. Koski
Jashodeep DATTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/020613 external-priority patent/WO2015139003A1/fr
Priority claimed from US14/985,303 external-priority patent/US20160252511A1/en
Application filed by Individual filed Critical Individual
Publication of CA2979676A1 publication Critical patent/CA2979676A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une méthode de diagnostic ou de traitement d'un sujet mammifère souffrant ou risquant de souffrir d'un cancer, comprenant les étapes consistant à générer une réponse lymphocytaire impliquant des lymphocytes Th1 CD4+ circulants anticancéreux à partir de cellules présentatrices d'antigènes ou de leurs précurseurs et des lymphocytes T CD4+ à partir d'un échantillon de sang dudit sujet qui provoque la sécrétion d'interféron-gamma (« IFN-? ») ; et à détecter ladite réponse lymphocytaire Th1 CD4+ anticancéreuse pour déterminer si ladite réponse est minorée. La présente invention concerne un procédé de restauration de la réponse immunitaire lymphocytaire Th1 CD4+ spécifique de HER2 chez un patient atteint d'un cancer du sein HER2-positif en ayant besoin. Ledit procédé comprend les étapes consistant à administrer au dit patient une quantité thérapeutiquement efficace d'un vaccin à base de cellules dendritiques (« CD ») comprenant des cellules dendritiques autologues pulsées avec des peptides de liaison du CMH de classe II dérivés de HER2 (« vaccination CD ») afin de renforcer la réponse lymphocytaire Th1 CD4+ anti-HER2 chez ledit patient ; et mesurer ladite réponse Th1 anti-HER2 chez ledit patient avant et après la vaccination CD pour déterminer l'ampleur du renforcement de ladite réponse.
CA2979676A 2015-03-13 2016-03-04 Methodes de suivi de la reponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire Abandoned CA2979676A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
WOPCT/US2015/020613 2015-03-13
US14/658,095 2015-03-13
PCT/US2015/020613 WO2015139003A1 (fr) 2014-03-14 2015-03-13 Méthodes de suivi de la réponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire
US14/658,095 US20150323547A1 (en) 2014-03-14 2015-03-13 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US14/985,303 US20160252511A1 (en) 2014-03-14 2015-12-30 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US14/985,303 2015-12-30
PCT/US2016/020987 WO2016153761A1 (fr) 2015-03-13 2016-03-04 Méthodes de suivi de la réponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire

Publications (1)

Publication Number Publication Date
CA2979676A1 true CA2979676A1 (fr) 2016-09-29

Family

ID=56978584

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979676A Abandoned CA2979676A1 (fr) 2015-03-13 2016-03-04 Methodes de suivi de la reponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire

Country Status (4)

Country Link
JP (1) JP2018515742A (fr)
CN (1) CN107533065A (fr)
CA (1) CA2979676A1 (fr)
WO (1) WO2016153761A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515421A (ja) * 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
RU2575978C2 (ru) 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
EP2872532A4 (fr) * 2012-07-10 2016-04-13 Oncotherapy Science Inc Peptides épitopes du cdca1 pour cellules th1 et vaccins les contenant
CA2942721A1 (fr) * 2014-03-14 2015-09-17 Czerniecki, Brian J. Methodes de suivi de la reponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire

Also Published As

Publication number Publication date
CN107533065A (zh) 2018-01-02
WO2016153761A1 (fr) 2016-09-29
JP2018515742A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
Melero et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer
Murray et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369–377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer
EP2373338B1 (fr) Annexina2 en tant que cible immunologique
US20150118244A1 (en) Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
AU2020244589A1 (en) Nant cancer vaccine
JP2022088665A (ja) がんの治療
Costa et al. The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives
US20170261508A1 (en) Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
CN104995203A (zh) 辅助性t细胞的活化方法
JP2007527225A (ja) Ｅｐｈａ２ｔ−細胞エピトープアゴニストおよびその使用
JP2020124193A (ja) 癌のｃｄ４＋ｔヘルパー１型応答の監視方法および免疫回復
AU2013357239B2 (en) Novel MHC-independent tumor-associated antigens
TW202210084A (zh) Cd30陽性癌症之治療
US20160252511A1 (en) Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
CA2979676A1 (fr) Methodes de suivi de la reponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire
AU2016244182B2 (en) Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
EP4527406A1 (fr) Vaccin contre le cancer utilisant un cocktail d'antigènes courants du cancer, un agent thérapeutique des cellules tcr/car-t, procédé de diagnostic compagnon et procédé de diagnostic du risque d'apparition du cancer par détection de cellules cancéreuses circulant dans le sang
EP3268464A1 (fr) Méthodes de suivi de la réponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire
Karyampudi et al. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102
TW202328438A (zh) 淋巴瘤之治療
CN116710475A (zh) Sqstm1及其在癌症疗法中的用途
WO2024083867A1 (fr) Biomarqueur
Sam CD27-CD70 interaction: novel predictive biomarker of immunotherapy in renal cell carcinoma and melanoma
Jung et al. Yeast-based identification of prostate tumor antigens provides an effective vaccine platform
Shaib et al. Peptide vaccines for treatment of colon cancer: Have we made progress?

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210304

FZDE Discontinued

Effective date: 20230707